Press Releases
FUJIFILM Diosynth Biotechnologies Texas Facility to Support COVID-19 Vaccine Candidate Manufacturing
FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, viral vaccines and gene therapies, announced that its College Station,...
News
Abzena receives growth capital investment from newly launched Biospring Partners
Abzena, a leading global partnership research organization providing integrated discovery, development and manufacturing of biologics and antibody drug conjugates (ADCs), has announced a $10M...
Press Releases
Sterling Signs Deal to Produce Potential COVID-19 Drug Candidate for Moleculin
Global contract development and manufacturing organisation (CDMO), Sterling Pharma Solutions has signed an agreement with Moleculin Biotech, Inc., to support the company’s expanded development...
News
CPhI Japan rescheduled for Spring 2021 with digital solutions to be launched
CPhI Japan organised by Informa Markets announces that, following a detailed review with partners and key industry stakeholders and to ensure the health and...
Press Releases
Cipla receives regulatory approval for launch of Ciplenza (Favipiravir 200 mg) in India to treat mild to moderate COVID-19
Cipla Limited announced that it has been granted regulatory approval by the Drug Controller General of India (DCGI) for the launch of Favipiravir in...
Clinical Trials
Glenmark Announces Top-Line Results From Phase 3 Clinical Trial of Favipiravir in Patients with Mild to Moderate COVID-19
Glenmark Pharmaceuticals Ltd. a global research-led pharmaceutical company announced top-line results from a Phase 3 clinical trial in mild to moderate COVID-19 patients conducted...
News
Optimus Pharma gets nod from DGCI to make COVID-19 drug ‘Favicovid’
Optimus Pharma said it has received the Drugs Controller General of India (DCGI) approval to manufacture and market Favipiravir 200 mg tablets for the...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read